投资公司 HC Wainwright 下调了 Hookipa Pharma 的目标价。 Investment firm HC Wainwright lowers price target for Hookipa Pharma.

HC Wainwright 将 Hookipa Pharma (NASDAQ:HOOK) 的目标价从 6.50 美元下调至 5.00 美元，而加拿大皇家银行则重申“跑赢大盘”评级，目标价为 5.00 美元。 HC Wainwright lowered its price target for Hookipa Pharma (NASDAQ:HOOK) from $6.50 to $5.00, while Royal Bank of Canada reaffirmed an "outperform" rating with a $5.00 target price. Hookipa Pharma 公布第一季度每股收益为 (0.11 美元)，而普遍预期为 (0.20 美元)，比预期高出 0.09 美元。 Hookipa Pharma reported Q1 EPS of ($0.11) vs. consensus estimates of ($0.20), beating expectations by $0.09. 该公司的市值为 7,976 万美元，市盈率为 -0.92，贝塔系数为 1.02。 The company has a market cap of $79.76 million, a price-to-earnings ratio of -0.92, and a beta of 1.02.